Knee Arthritis, Knee Osteoarthritis
Conditions
Brief summary
The study will be conducted to answer the following questions: * Is there an effect of phonophoresis using glucosamine on pain level , function and range of motion in knee osteoarthritis patients ? * Is there an effect of phonophoresis using chitosan on pain level , function and range of motion in knee osteoarthritis patients ? * Is there a difference between the effect of phonophoresis using glucosamine and phonophoresis using chitosan on pain level , function and range of motion in knee osteoarthritis patients ?
Interventions
DEVICEPhonophoresis with chitosan
Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
DEVICEPhonophoresis with glucoasmine
Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
PROCEDUREConventional Physical Therapy
Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
Sponsors
October 6 University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
45 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* unilateral or bilateral grade II knee osteoarthritis (clinical and imaging diagnosis X-ray). * knee pain intensity ≥ 5 on the Visual Analogue Scale (VAS)
Exclusion criteria
* Anterior Cruciate Ligament (ACL) and meniscus injury * use of oral or injected corticosteroids in the last 3 months * history of knee surgery or fracture * acute infectious synovitis or arthritis conditions * presence of malignancy * individuals with, topical lesions, contact dermatitis and history of cutaneous hypersensitivity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Visual Analog Scale | Baseline and Change from baseline pain scores at four weeks | The visual analog scale (VAS) is a pain rating scale first used by Hayes and Patterson in 1921. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-no pain on the left end (0 cm) of the scale and the worst pain on the right end of the scale (10 cm). |
| Change in WOMAC INDEX | Baseline and Change from baseline scores at four weeks | The WOMAC VA 3.1 Index score (WOMAC INDEX) is the sum of WOMAC A (total pain), WOMAC B (stiffness) and WOMAC C (functional impairment) subscores. The WOMAC INDEX score ranges from 0 to 2400 mm, with higher scores indicating higher disease burden. |
| Range of Motion at knee joint both in extension and flexion | Baseline and Change from baseline scores at four weeks | The ROM will be measured using the Baseline 12-1056 bubble inclinometer. Patients will be in prone position and will be instructed to move their leg away from the thigh to measure extension range of motion and move the leg toward the thigh to measure flexion |
Countries
Egypt
Outcome results
None listed